FDA approves Rituxan plus chemo for pediatric cancer indications

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”
Whistleblowers will be “honored”

As he addressed FDA employees, HHS Secretary Robert F. Kennedy Jr. described the Trump era as a “generational opportunity to make the regulatory agency live up to its foundational ideals” and emerge from the morass of what he described as the “deep state.”

FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC

FDA on April 11 approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.

April 18, 2025

Vol.51 No.15

Drugs & Targets

FDA to phase out animal testing requirement for monoclonal antibodies, other drugs

FDA announced on April 10 its efforts to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.

April 18, 2025

Vol.51 No.15

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing

Nov. 6, 2023, was a bad day for Tom Curran, a charming scientist with a lilting Scottish brogue and the lifelong dream of curing childhood cancers.

April 11, 2025

Vol.51 No.14

By Claire Marie Porter

Cancer Policy

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

A federal judge ruled that the FDA lacks the statutory authority to regulate laboratory developed tests, finding squarely in favor of plaintiffs in the consolidated lawsuits brought by American Clinical Laboratories Association, Association for Molecular Pathology, and others. ASCP submitted an amicus brief supporting the plaintiffs.

April 11, 2025

Vol.51 No.14

Clinical Roundup

Pediatric oncology programs lack sufficient psychosocial resources, Nemours Children’s Health study finds

Families facing a childhood cancer diagnosis experience a range of psychological, social, and emotional stressors, from anxiety to financial strain to sibling concerns.

April 11, 2025

Vol.51 No.14

FDA approves Rituxan plus chemo for pediatric cancer indications

YOU MAY BE INTERESTED IN

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”
Whistleblowers will be “honored”

FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC

FDA to phase out animal testing requirement for monoclonal antibodies, other drugs

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

Pediatric oncology programs lack sufficient psychosocial resources, Nemours Children’s Health study finds

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Rituxan plus chemo for pediatric cancer indications

YOU MAY BE INTERESTED IN

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”Whistleblowers will be “honored”

FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC

FDA to phase out animal testing requirement for monoclonal antibodies, other drugs

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s MercyWhistleblower lawsuit alleges wrongful firing

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

Pediatric oncology programs lack sufficient psychosocial resources, Nemours Children’s Health study finds

Never miss an issue!

Login

RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”
Whistleblowers will be “honored”

Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing